Mainstream supplement brand
Nutrafol is a subscription-based hair-growth supplement brand that markets itself heavily on its own sponsored clinical studies and dermatologist recommendations, sold direct-to-consumer as a recurring subscription.
quality claims we could confirm ourselves, rather than repeat from the vendor's marketing.
Hair-growth-focused supplement capsules, sold as a recurring monthly subscription, segmented into product lines for men, women and postpartum.
This is an informational review of a mainstream, widely available consumer brand, not a research-use-only or prescription product. Nothing here is medical advice, and nothing here should be read as an endorsement to buy. We describe what the brand says about itself and what we could find in the public record, and we separate the two.
Graded by whether we could confirm it ourselves or are only repeating what the vendor states. A vendor's honesty about its own testing is a different question from what a published trial shows, so this is a separate scale from the evidence grades on our guides.
Nutrafol's marketing repeatedly references company-sponsored study results. A brand-sponsored study is a real study, but it is a different evidentiary standard than an independent, unaffiliated trial; we did not read the underlying study methodology for this entry.
Where the vendor states thisAs a subscription-first product, cancellation terms and the ongoing (not just first-month) price matter; read Nutrafol's own subscription terms carefully before signing up.
Study results cited in Nutrafol's own marketing come from research it sponsored; that is disclosed but is a different standard than an independent trial.
Nutrafol discloses that the studies it cites are its own sponsored research, not independent, unaffiliated trials. That distinction matters when weighing the claims.
Every fact above traces to one of these pages, published by the vendor itself and checked on September 27, 2026. Vendor policy pages change without notice, so if something here looks out of date, it probably is.
Compare against
Open pricing, public COAs, strict research-only gate
